Up to half of women with multiple sclerosis (MS) who stop treatment with Gilenya (fingolimod) when planning to become pregnant will experience a relapse during pregnancy, according to a new study.
The findings also revealed relapses over the first six months after giving birth in a quarter of women who stopped Gilenya before or after getting pregnant.
The research, “Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis,” was presented at the 34th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which took place Oct. 10-12, in Berlin, Germany.
The data were presented by Spalmai Hemat, from St. Josef Hospital, Ruhr University of Bochum, Germany.
Previous studies have shown that the frequency of symptoms’ worsening (relapses) in MS patients declines during pregnancy, creating a sort of natural protection. “In pregnant women with MS, disease activity significantly decreases, especially in the third trimester” Hemat
... read more at: https://multiplesclerosisnewstoday.com/deltasone-prednisone-ms